Officially established in Thailand on late 2000, ATB Oncology, referred as American Taiwan Biopharm Co.,Ltd.  is a joint venture between TTY Biopharm Co., Ltd. from Taiwan and Wells Healthcare Inc., USA.  

ATB Oncology always strives to dedicate itself to its partners by providing good quality medicines to all patients at reasonable costs, new medical options for physicians, rewarding careers to employees, and increased value to its shareholders.

Dedicated to advancing sciences and medicines to help people live better lives, the company is concentrated on several therapeutic areas such as cancer, supportive care and infectious diseases. The company has six currently marketed oncology products and an advancing pipeline of promising candidates, all designed to treat or prevent a number of Asian prevalent diseases.

The company’s currently flagship oncology product is  Oxalip (Oxaliplatin) for patients with metastatic colorectal cancer or patients, who require adjuvant treatment after completing primary surgery. Further, the company’s marketed oncology products include Lipo – Dox(Pegylated Liposomal DoxorubicinHCl),UFUR(Tegafur plus Uracil),Hexalen (Altretamine) and Folina(Calcium Folinate), with additional products in portfolio.

Having continuously made significant growth in the last several years, ATB Oncology is now a fully integrated company with ability and infrastructure to take a product from early clinical development through manufacturing, and into the market via our oncology, hospital – based sales forces.

We believe ATB Oncology will continue to build and grow by its dedication to advances in technology and patient care, its drive to increase shareholder value while maintaining its concentration on improving the quality of life of even the smallest patients, and the desire of its employees to make a difference.

DOWNLOAD     Company Profile.pdf (3.07 MB)